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Replacement of donor lymphoid 
tissue in small-bowel transplants 
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The presence of recipient lymphocytes in grafts is 
thoughtto equate with rejection. Thus, we wished to 
follow the fate of lymphocytes after transplant of 
the small bowel. Three complete small-bowel 
transplants, two with the liver from the same donor 
also transplanted, were done successfully. Patients 
were immunosuppressed with FK 506. 5 to 11 % of 
lymphocytes in the recipients' peripheral blood were 
of donor origin during the early postoperative period 
when there were no clinical signs of graft-versus-
host disease. However, donor cells were no longer 
detectable after 12 to 54 days. Serial biopsy 
specimens of the grafted small bowel showed 
progressive replacement of lymphocytes in the 
lamina propria by those of the recipient's HLA 
phenotype. Lymphoid repopulation was complete 
after 10 to 1 2 weeks but the epithelial cells of the 
intestine remained those of the donor. The patients 
are on enteral alimentation after 5, 6, and 8 months 
with histopathologically normal or nearly normal 
intestines. Re-examination of assumptions aboutthe 
rejection of intestinal grafts and strategies for its 
prevention are required following these 
observations. 
Lancet 1991; 337: 818-19. 
Little is known about the fate and function of 
lymphocytes in intestinal grafts, partly because long-tenn 
survival after transplant of the small intestine has been 
difficult to achieve. The first successful complete small-
intestine transplant in man1 was accomplished with 
continuous intravenous infusion of cyclosporin. The patient 
briefly had donor lymphocytes in peripheral blood during 
the early postoperative phase and at the same time had 
symptoms of graft-versus-host disease (GVHD). We have 
110 cases. AmJ Moo 1977; 62: 20<Hl8. 
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left ventricular filling dynamics. Am Heart J 1989; 118: 92-98. 
10. Hausdorf G, MOrf G, Beron G, et at Long-term doxorubicin 
cardiotoxicity in childhood: non-invasive evaluation of the contractile 
state and diastolic filling. Br Heart J 1988; 60: 309-15. 
followed the fate of host and donor lymphocytes in three 
patients treated with FK 506-0ne after small-bowel 
transplant and two after combined liver-intestine grafting. 
Patient 1 lost the entire small bowel and most of the colon 5 
months before transplant after a gun shot wound of the superior 
mesenteric artery; liver function was nonnal. Patients 2 and 3 had 
had total small-bowel resection several years earlier because of 
necrotising enterocolitis and thrombosis of the superior mesenteric 
artery, respectively, and both had liver failure following parenteral 
hyperalimentation. All grafts received arterial blood from the aorta, 
and intestinal venous outflow was through the liver of patient 1 or 
through the liver grafts of patients 2 and 3. FK 506 for 
immunosuppression was given intravenously at first (0· 1 mgfkg per 
day) and later enterally (0'3 mg/kg per day in divided doses). 
Maintenance doses ofFK 506 were lower. Prednisolone was given 
initially and later stopped (patients 2 and 3) or reduced (patient 1). 
Patients were maintained on intravenous nutrition for at least 2 
months before starting jejunostomy and, ultimately, oral feeding. 
Patients 1 and 2 have had nonnal gastrointestinal continuity 
restored, and patient 3 is still being fed through a nasogastric tube 
with its tip advanced into the graft jejunum. 
Peripheral blood lymphocytes were isolated with 'Ficoll-
Hypaque' (Phannacia LKB) and stored in liquid nitrogen until 
tested. Lymphocytes were added to monoclonal antibodies (One 
Lambda Inc, Los Angeles), fixed in 2% parafonnaldehyde-
phosphate buffer solution, and identified by flow cytometry 
('FACScan', Becton Dickinson). Monoclonal antibodies were also 
used for immunocytochemical identification of lymphocyte HLA 
phenotypes in biopsy specimens obtained through jejunal and ileal 
stomas. 
During the first week after transplant, between 5 and 11 % 
of the circulating lymphocytes of all patients were of the 
donor type (figure). However, after 12-54 days donor 
lymphocytes were no longer detectable. The proportion of 
donor lymphocytes in the lamina propria of patient 1 
decreased from 80% at 21 days post-transplant to 30% after 
35 days and 0% after 70 days (figure). Jejunal and ileal 
biopsies showed the same pattern of change. Donor 
lymphocytes were replaced by host lymphocytes in patients 
2 and 3 after 77 and 84 days, respectively. 
Our finding of recipient lymphocyte repopulation of 
chronically functioning intestinal grafts, and similar results 
in rats treated with FK 506,2 indicate that presence of 
recipient lymphocytes in the graft does not necessarily 
equate with rejection.3 What do we know about the fate and 
function of the lymphoid component of intestinal or 
mutlivisceral grafts? In non-immunosuppressed dogs 
receiving multivisceral transplants the intestine was rejected 
and there was histopathological evidence ofGVHD within 1 
week.4 Subsequently, the consequences of GVHD (parent 
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Proportion of donor lymphocytes in peripheral blood and 
lamina propria after small-bowel transplant (patient 1). 
to F 1 hybrid) were separated from those of rejection (F 1 to 
parent) in inbred rats.5 The design of these experiments 
rendered either the recipient or intestinal graft vulnerable to 
immunological attack by the other, whereas under clinical 
circumstances both immune systems are activated. It is 
unlikely that alteration of the graft lymphoid system could 
be achieved more efficiently by pretransplant manipUlations 
(such as irradiation or antilymphocyte globulin) than 
occurred with the use of potent immunosuppression in our 
patients and in rats.2 Donor pretreatment was not used in the 
three cases we report, nor in a fourth with only 7 weeks of 
follow-up. GVlID was not encountered. Histocompatible 
bone-marrow transplant experiments in rats show that FK 
506 given prophylactically prevents GVlID.6 Established 
GVlID has been reversed with FK 506 in human 
bone-marrow recipients.? This may be important if, as 
seems likely, the migrated donor lymphocytes have survived 
and are diffusely established in recipient tissue. 
Lymphoreticular repopulation is not a unique feature of 
intestinal or multivisceral grafts. The macrophage system in 
human liver grafts switches completely to that of the 
recipient within 100 days. 8 Fung et a19 •lO have described graft 
lymphoid tissues in transition after human heart-lung and 
liver transplant. Thus, lymphoreticular repopulation 
probably occurs with successful transplant of any lymphoid-
containing graft. Whether this contributes to graft 
acceptance should be the subject for future inquiry. 
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Oncogene expression in cervical 
intraepithelial neoplasia and 
invasive cancer of cervix 
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Expression of the oncogenes Ha-RAS, c-MYC, and 
ERB-2 was investigated with an automated image 
analysis system in 12 specimens of normal cervix, 10 
of cervical intraepithelial neoplasia (CI N) grade 1,24 
of CI N 3, and 10 of invasive cancer of the cervix. 
There was amplification of all three onocogenes in 
CI N 3 and invasive cancer compared with normal 
cervix and CIN 1. The difference was most 
pronounced with an antibody to the RAS p21 
protein, with no overlap between CIN 3 and the 
normal range. This method might be useful in 
screening for cervical neoplasia, and for the 
determination of which CIN lesions require 
treatment. 
Lancet 1991; 337: 819--20. 
Altered oncogene acuvtty has been noted in many 
malignant diseasesl as well as in premalignant states such as 
villous adenoma of the rectuml and atypical hyperplasia of 
the endometrium.3 Several workers have shown altered 
Ha-RAS and c-MYC expression in malignant disease of the 
cervix4 and have related this to prognosisS-7 and cell type.8 
Cervical intraepithelial neoplasia (CIN) has also been 
studied, with conflicting results.4•9 •lo 
We investigated expression of the oncogenes Ha-RAS, 
c-MYC, and ERB-2 in histological sections of normal cervix 
(n = 12), cervical intraepithelial neoplasia (10 CIN 1 and 24 
CIN 3), and invasive cancer of the cervix (10) to see if there 
was a difference that could be helpful in screening, 
treatment, or prognosis. 
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RAS. (upper). MYC (middle). and ERB (lower) expression in 
cervix. 
*p<O·OOOl. RAS. MYC. vs normal; *p<0·005 vs normal; 
**p < 0'0005 ERB vs normal. 
Normal cervical tissue was obtained from patients with no history 
of cervical neoplasia and who were undergoing hysterectomy for 
benign disease. The histological diagnosis of normal cervix, CIN, or 
invasive cancer was ronfinned on haematoxylin and eosin stained 
slides of adjacent sections of tissue. Slides were deparaffinised and 
rehydrated, then incubated for 40 minutes each with a murine 
monoclonal antibody (IgG or IgM) specific for the onroprotein 
(P21 for Ha-RAS, Stratech, London; p45 for c-MYC and plS5 for 
ERB-2, Cambridge Research Biochemicals), biotinylated anti-
mouse IgG or IgM, and streptavidin-Texas red or fluorescein 
isothiocyanate (Amersham UK, and Sigma UK, Dorset), with 
thorough washing in phosphate-buffered saline between steps. 
With this method, one slide rould be stained for two onroproteins. 
The slides were examined with a fluorescent microsrope with a 
x 50 water immersion objective, and a 'System 3' image analyser 
(Micro Measurements, Saffron Waldren, Essex). Fields were 
visually selected, the detector level was set to display fluorescent 
areas without background interference, and the results were 
expressed as a percentage, which was equivalent to the mean 
intensiry per unit area of ten adjacent non-overlapping fields. 
Results were analysed with the Mann Whitney U test for 
non-parametric data. 
The results for the three oncogenes are shown in the 
figure. For Ha-RAS, normal cervix and CIN 1 had closely 
similar levels of activity; CIN 3 and invasive cancer showed 
increased activity, but did not differ significantly. The 
CIN 3/invasive range did not overlap with the range for 
normal cervix. For c-MYC, results for normal/CIN 1 
and CIN 3/invasive cancer differed significantly, but there 
was some overlap between normal and CIN 3. With ERB-2, 
CIN 3/invasive cancer results were significantly different 
from those for the normal cervix, although ·there was 
obvious overlap between the three groups. 
With this method of fluorescent antibody staining of 
oncoproteins, amplification of the oncogenes Ha-RAS, 
c-MYC, and ERB-2 in malignant and premalignant cervical 
epithelium is seen when compared with the normal cervix. It 
has been suggested that CIN should be reclassified as 
low-grade and high-grade, reflecting the different malignant 
potential. Our findings of similar staining of CIN I and 
normal epithelium would perhaps support the theory that 
progression to high-grade CIN is not inevitable. All the 
invasive cancers studied had a high level of c-MYC and 
Ha-RAS expression, so it is unlikely that this method can 
provide a useful prognostic indicator. Since all the specimens 
of CIN 3 and invasive cancer showed increased Ha-RAS 
expression, with no overlap with the normal range, it may be 
that this method could be adapted for screening. We plan to 
apply this technique to cervical cytology smears to see if it can 
reliably identify patients with high-grade CIN. 
This work would not have been possible without the cooperation of Dr J. 
Scholefie1d of the Department of Biomedical Instrumentation at Strathclyde 
Univenrity, and Dr F. Lee and the Pathology Department at Glasgow Royal 
Infinnary. 
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